Autoimmune hepatitis type 3

Summary

Autoimmune hepatitis type 3 (MONDO:0021177) is a disease. A subtype of autoimmune hepatitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	autoimmune hepatitis type 3
Mondo ID	MONDO:0021177
ICD-11	607786920
SNOMED CT	721713007
UMLS	C4303162
MedGen	928831
GARD	0025298
Is cancer (heuristic)	no

Also known as: autoimmune hepatitis type 3

Disease family

This is a subtype of autoimmune hepatitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › endocrine system disorder › autoimmune disorder of endocrine system › autoimmune hepatitis › autoimmune hepatitis type 3

Related subtypes (6): autoimmune hepatitis type 1, autoimmune hepatitis type 2, primary biliary cholangitis/primary sclerosing cholangitis and autoimmune hepatitis overlap syndrome, seronegative autoimmune hepatitis, autoimmune cholangitis, giant cell hepatitis with autoimmune hemolytic anemia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.